Medical News

RSS

Sorin Group acquires Gish Biomedical from Ventizz Capital Partners

Sorin Group, a global company and a leader in the treatment of cardiovascular diseases, announced today that it has acquired Gish Biomedical from Ventizz Capital Partners, a private equity group focused on technology-oriented companies.

8 Jun 2010

Evidence-based oral health guidelines for pregnant women

Health care providers now have evidence-based guidelines to emphasize the importance of pregnant women maintaining good oral health care and the safety of providing appropriate treatment during pregnancy as published in the June Journal of the California Dental Association.

8 Jun 2010

$Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010$

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.

8 Jun 2010

Vertellus announces new 3-cyanopyridine production unit at Nantong facility

Vertellus Specialties Inc. announced today that it will break ground on a new 3-cyanopyridine production unit at Vertellus' production facility in Nantong, Jiangsu, China. This unit is a continuation of a larger effort to expand production capacity in Nantong. It will increase Vertellus' Vitamin B3 manufacturing capacity in the region by 10,000 metric tons. The capacity increase will enable Vertellus to maintain its position as the world's second largest provider of Vitamin B3 and the largest producer of cyanopyridines in the world.

8 Jun 2010

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.

8 Jun 2010

La Jolla Institute scientist finds protein key to insulin secretion

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx, Inc. today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine (GTx-024) is GTx's lead selective androgen receptor modulator (SARM) which the company is developing for the treatment of cancer cachexia.

8 Jun 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Women who quit smoking during pregnancy will prevent infant deaths

If more women quit smoking before they became pregnant, it would save infant lives, concludes a new study from the Centers for Disease Control and Prevention (CDC).

8 Jun 2010

Gail Donner receives Jeanne Mance Award for her positive impact on practice of nursing in Canada

Gail Donner will receive Canada's most prestigious nursing award, the Jeanne Mance Award, for her positive impact on the practice of nursing in Canada.

8 Jun 2010

New federal health care reform law covers large number of Americans at lower cost: RAND study

The recently enacted federal health care reform law provides health insurance coverage to the largest number of Americans while keeping federal costs as low as reasonably possible, according to a new analysis from the RAND Corporation.

8 Jun 2010

Opinions: Improving maternal health

"Delivering A Better Future For Women and Girls," East African (Manguyu, 6/7).

8 Jun 2010

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

A rare but fatal disease of blood vessels in the lung may be caused in part by aberrant silencing of genes rather than genetic mutation, new research reports. Pulmonary arterial hypertension, a syndrome characterized by gradual blockage of blood vessels in the lungs, has been linked to genetic causes in a small percentage of patients. But University of Chicago researchers have now found that a form of epigenetics - the modification of gene expression - causes the disease in an animal model and could contribute to the disease in humans.

8 Jun 2010

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors.

8 Jun 2010

Quintiles announces comprehensive suite of PI3K biomarker assays

Quintiles today announced a comprehensive suite of biomarker assays to help biopharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.

8 Jun 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

FSPs designed to improve residential stability, mental health outcomes for homeless persons with mental illness

Full-Service Partnerships are designed to do 'whatever it takes' to improve residential stability and mental health outcomes for homeless persons with serious mental illness. They are the cornerstone of California's Mental Health Services Act - one of the largest mental health policy experiments in recent history.

8 Jun 2010

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Threshold Pharmaceuticals, Inc. today announced results from Phase 1/2 clinical trials in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented during the American Society for Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.

8 Jun 2010

Rice University students develop new device to help children with acute respiratory infections

Gently, gently. That's how babies should be handled, and it was the prime consideration when a team of Rice University seniors developed a device that could save babies' lives.

8 Jun 2010

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).

8 Jun 2010

Medical News

Sorin Group acquires Gish Biomedical from Ventizz Capital Partners

Evidence-based oral health guidelines for pregnant women

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Vertellus announces new 3-cyanopyridine production unit at Nantong facility

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

La Jolla Institute scientist finds protein key to insulin secretion

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Women who quit smoking during pregnancy will prevent infant deaths

Gail Donner receives Jeanne Mance Award for her positive impact on practice of nursing in Canada

New federal health care reform law covers large number of Americans at lower cost: RAND study

Opinions: Improving maternal health

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Quintiles announces comprehensive suite of PI3K biomarker assays

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

FSPs designed to improve residential stability, mental health outcomes for homeless persons with mental illness

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Rice University students develop new device to help children with acute respiratory infections

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News